Our HSA-CXCL8 fusion construct is thought to displace the naturally occurring CXCL8 from the surface of GAGs present and often overexpressed in the tumor and thus blocking peripheral blood mononuclear cell (PBMC) influx, which is studied in combination with a marketed PD-1 antibody that circumvents the T-cell blockade and reinstalls T-cell function. This evidence concerns the gene PDCD1 and neoplasm.